Skip to main content
. 2022 Mar 17;11:e71282. doi: 10.7554/eLife.71282

Figure 6. AdipoRon activates AMPK, increases the expression of Ppargc1a, and activates PGC-1a gene targets in diverse cultured cells.

Figure 6.

(A) RT-PCR detection of adiponectin receptors in NIH-3T3 fibroblast, day 7 differentiated C2C12 myotubes, and rhesus monkey peripheral blood mononuclear cells (PBMCs) (n=7, 7, and 4, respectively), (B) phosphorylation of AMPK at Thr172 after AdipoRon treatment (10 or 50 µm) for 10 min (n=3 per group) in NIH-3T3 fibroblasts, (C) transcript levels of Ppargc1a and its gene targets after 90 min of AdipoRon treatment (10 or 50 µm, n=4–5 per group, relative to Rn18s RNA), (D) phosphorylation of AMPK at Thr172 after AdipoRon treatment for 10 min in day 7 differentiated myotubes (n=3 per group), (E) transcript levels of Ppargc1a and its gene targets after 90 min of AdipoRon treatment (10 or 50 µm, n=7 per group, relative to Rn18s RNA), (F) mitochondrial membrane potential measured by TMRE assay at 2 and 4 hr of AdipoRon treatment (n=7 per group), (G) RT-PCR detection of myosin isoforms relative to Rn18s in day 7 differentiated myotubes, (H) phosphorylation of AMPK at Thr172 after AdipoRon treatment (10 or 50 µm) for 10 min in cultured rhesus monkey PBMCs (n=3–4 per group), and (I) transcript levels of Ppargc1a and PGC1a gene targets after 60 min of AdipoRon treatment (n=3–4 per group). Data shown as average ± SEM (*p<0.05).